Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851591)
Watch
English
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
scientific article
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
21030459
retrieved
13 November 2016
title
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
(English)
1 reference
stated in
PubMed
PubMed ID
21030459
retrieved
13 November 2016
author
Pasi A Jänne
series ordinal
14
object named as
Pasi A Jänne
0 references
Nathanael Gray
series ordinal
7
object named as
Nathanael S Gray
0 references
Keith D Wilner
series ordinal
8
object named as
Keith Wilner
0 references
James G Christensen
series ordinal
9
object named as
James G Christensen
0 references
George D Demetri
series ordinal
10
object named as
George Demetri
0 references
author name string
Takaaki Sasaki
series ordinal
1
0 references
Katsuhiro Okuda
series ordinal
2
0 references
Wei Zheng
series ordinal
3
0 references
James Butrynski
series ordinal
4
0 references
Marzia Capelletti
series ordinal
5
0 references
Liping Wang
series ordinal
6
0 references
Geoffrey I Shapiro
series ordinal
11
0 references
Scott J Rodig
series ordinal
12
0 references
Michael J Eck
series ordinal
13
0 references
language of work or name
English
0 references
publication date
15 December 2010
0 references
published in
Cancer Research
0 references
volume
70
0 references
page(s)
10038-43
0 references
issue
24
0 references
cites work
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Activating mutations in ALK provide a therapeutic target in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
20 March 2017
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
7 April 2017
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
29 September 2017
A mouse model for EML4-ALK-positive lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
29 September 2017
Oncogenic mutations of ALK kinase in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
29 September 2017
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
29 September 2017
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045808
retrieved
2 June 2018
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21030459
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/0008-5472.CAN-10-2956
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2951169
OpenCitations bibliographic resource ID
2951169
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2951169
PMCID
3045808
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2951169
PubMed ID
21030459
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2951169
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit